poisar

Stocks · News reference

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline

BenzingaVandana Singh

Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — InMed Pharmaceuticals Inc. (INM)

    Filed: 2026-07-22 AccNo: 0001213900-26-080414 Size: 303 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits